Exciting TimesLove this part of the release.....
We are very pleased with these initial results that indicate GAP-107B8 is showing therapeutic efficacy against ovarian cancer cells implanted in mice and allowed to grow tumours. The success rate of curing women with ovarian cancer using currently available therapies is still very low, and so the identification of a possible new treatment is exciting and warrants more investigation. We are looking forward to continue working with PharmaGap on this exciting drug program."